Treatments a and B Are Two New Investigational Drugs Being

Treatments A and B are two new investigational drugs being evaluated for the treatment of an unique respiratory virus infection in children that causes abrupt respiratory collapse and mortality. The 2-week survival following treatment is analyzed as part of the testing procedure to establish the clinical effectiveness of the investigational medications. A total of 60 children who have just been diagnosed with the condition are randomly randomized to take Drug A, Drug B, or placebo in a 1:1:1 ratio.   which of the following statements comparing the effectiveness of Drugs A and B in treating children infected with the novel virus is most appropriate?

A) Drugs A and B require treating the same number of children to prevent 1 additional death, so they are equally effective
B) Drug A requires treating fewer children to prevent 1 additional death compared to Drug B, so Drug A is less effective than Drug B
C) Drug A requires treating fewer children to prevent 1 additional death compared to Drug B, so Drug A is more effective than Drug B
D) Drug A requires treating more children to prevent 1 additional death compared to Drug B, so Drug A is less effective than Drug B
E) Drug A requires treating more children to prevent 1 additional death compared to Drug B, so Drug A is more effective than Drug B